Stock Scorecard
Stock Summary for MoonLake Immunotherapeutics - Class A (MLTX) - $19.30 as of 4/10/2026 6:29:35 PM EST
Total Score
10 out of 30
Safety Score
30 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for MLTX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for MLTX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for MLTX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for MLTX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for MLTX (30 out of 100)
| Stock Price Rating (Max of 10) | 6 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for MLTX
Financial Details for MLTX
Company Overview |
|
|---|---|
| Ticker | MLTX |
| Company Name | MoonLake Immunotherapeutics - Class A |
| Country | N/A |
| Description | MoonLake Immunotherapeutics is a pioneering biotechnology company focused on developing innovative therapies for chronic inflammatory diseases using its proprietary drug delivery platform. The firm is currently advancing its lead product candidate, a novel interleukin-17 inhibitor, through clinical trials, aiming to provide transformative treatment solutions that could significantly enhance patient outcomes. With a strong research pipeline and strategic partnerships, MoonLake is well-positioned to impact the immunotherapy market, addressing critical unmet medical needs while creating substantial value for shareholders. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 12/31/2025 |
| Next Earnings Date | 5/11/2026 |
Stock Price History |
|
| Last Day Price | 19.30 |
| Price 4 Years Ago | 10.50 |
| Last Day Price Updated | 4/10/2026 6:29:35 PM EST |
| Last Day Volume | 1,695,848 |
| Average Daily Volume | 1,131,546 |
| 52-Week High | 62.75 |
| 52-Week Low | 5.95 |
| Last Price to 52 Week Low | 224.37% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 37.55 |
| Sector PE | 56.25 |
| 5-Year Average PE | -30.41 |
| Free Cash Flow Ratio | 4.14 |
| Industry Free Cash Flow Ratio | 16.19 |
| Sector Free Cash Flow Ratio | 19.70 |
| Current Ratio Most Recent Quarter | 9.27 |
| Total Cash Per Share | 4.66 |
| Book Value Per Share Most Recent Quarter | 4.27 |
| Price to Book Ratio | 4.09 |
| Industry Price to Book Ratio | 2.89 |
| Sector Price to Book Ratio | 8.32 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 8.59 |
| Sector Price to Sales Ratio Twelve Trailing Months | 23.35 |
| Analyst Buy Ratings | 11 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 71,728,000 |
| Market Capitalization | 1,384,350,400 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -91.13% |
| Reported EPS 12 Trailing Months | -3.68 |
| Reported EPS Past Year | -3.52 |
| Reported EPS Prior Year | -1.89 |
| Net Income Twelve Trailing Months | -227,320,000 |
| Net Income Past Year | -227,318,000 |
| Net Income Prior Year | -118,935,517 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 334,517,000 |
| Total Cash Past Year | 334,517,000 |
| Total Cash Prior Year | 180,426,449 |
| Net Cash Position Most Recent Quarter | 260,417,000 |
| Net Cash Position Past Year | 260,417,000 |
| Long Term Debt Past Year | 74,100,000 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 74,100,000 |
| Equity to Debt Ratio Past Year | 0.80 |
| Equity to Debt Ratio Most Recent Quarter | 0.80 |
| Total Stockholder Equity Past Year | 304,481,000 |
| Total Stockholder Equity Prior Year | 446,825,002 |
| Total Stockholder Equity Most Recent Quarter | 304,481,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -196,042,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.73 |
| Free Cash Flow Past Year | -196,042,000 |
| Free Cash Flow Prior Year | -117,106,783 |
Options |
|
| Put/Call Ratio | 0.14 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.26 |
| MACD Signal | 0.14 |
| 20-Day Bollinger Lower Band | 12.68 |
| 20-Day Bollinger Middle Band | 16.29 |
| 20-Day Bollinger Upper Band | 19.91 |
| Beta | 1.19 |
| RSI | 52.10 |
| 50-Day SMA | 28.78 |
| 150-Day SMA | 41.74 |
| 200-Day SMA | 34.51 |
System |
|
| Modified | 4/14/2026 3:25:49 AM EST |